Such an obsession

Same author

Pharmacological activation of p53 induces dose-dependent changes in endothelial cell fate during angiogenic sprouting.

Cell death & disease·2025

Same author

Confirmation by conformation: rescue of mutant p53 in AML.

Blood·2025

Same author

Editor's Note: The MDM2/MDMX-p53 Antagonist PM2 Radiosensitizes Wild-Type p53 Tumors.

Cancer research·2025

Same author

CDK11 inhibition induces cytoplasmic p21WAF1 splice variant by p53 stabilisation and SF3B1 inactivation.

Molecular oncology·2025

Same author

The legacy of a gentleman scientist: Pierre Hainaut.

Cell death and differentiation·2025

Same author

Engineered Peptide Coacervates Enable Efficient Intracellular Delivery of the MYC Inhibitor omoMYC.

Molecular pharmaceutics·2025

Same journal

Effective treatment of human breast tumors by chimeric CCL2 and CCL8 diphtheria toxin cytotoxic peptides.

Cancer biology & therapy·2026

Same journal

NSUN2 mediates SALL2 m5C methylation to inhibit ferroptosis and promote breast cancer progression.

Cancer biology & therapy·2026

Same journal

Targeting the PI3K/AKT pathway in prostate cancer: the role of PTEN deficiency and biomarker-guided therapy.

Cancer biology & therapy·2026

Same journal

ABHD17C regulates the efficacy of lenvatinib in suppressing hepatocellular carcinoma.

Cancer biology & therapy·2026

Same journal

Advances in SEC61G research: from ER translocon subunit to emerging pan-cancer oncogenic roles.

Cancer biology & therapy·2026

Same journal

Efficacy and safety profiles of CDK4/6 inhibitor in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC) from the high-altitude versus low-altitude regions: a multi-center retrospective study.

Cancer biology & therapy·2026

Related Experiment Videos

Such an obsession

Related Concept Videos

Pharmacological activation of p53 induces dose-dependent changes in endothelial cell fate during angiogenic sprouting.

Confirmation by conformation: rescue of mutant p53 in AML.

Editor's Note: The MDM2/MDMX-p53 Antagonist PM2 Radiosensitizes Wild-Type p53 Tumors.

CDK11 inhibition induces cytoplasmic p21<sup>WAF1</sup> splice variant by p53 stabilisation and SF3B1 inactivation.

The legacy of a gentleman scientist: Pierre Hainaut.

Engineered Peptide Coacervates Enable Efficient Intracellular Delivery of the MYC Inhibitor omoMYC.

Effective treatment of human breast tumors by chimeric CCL2 and CCL8 diphtheria toxin cytotoxic peptides.

<i>NSUN2</i> mediates <i>SALL2</i> m5C methylation to inhibit ferroptosis and promote breast cancer progression.

Targeting the PI3K/AKT pathway in prostate cancer: the role of PTEN deficiency and biomarker-guided therapy.

ABHD17C regulates the efficacy of lenvatinib in suppressing hepatocellular carcinoma.

Advances in SEC61G research: from ER translocon subunit to emerging pan-cancer oncogenic roles.

Efficacy and safety profiles of CDK4/6 inhibitor in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC) from the high-altitude <i>versus</i> low-altitude regions: a multi-center retrospective study.

Related Experiment Videos

Such an obsession

Related Concept Videos

Related Articles

Pharmacological activation of p53 induces dose-dependent changes in endothelial cell fate during angiogenic sprouting.

Confirmation by conformation: rescue of mutant p53 in AML.

Editor's Note: The MDM2/MDMX-p53 Antagonist PM2 Radiosensitizes Wild-Type p53 Tumors.

CDK11 inhibition induces cytoplasmic p21<sup>WAF1</sup> splice variant by p53 stabilisation and SF3B1 inactivation.

The legacy of a gentleman scientist: Pierre Hainaut.

Engineered Peptide Coacervates Enable Efficient Intracellular Delivery of the MYC Inhibitor omoMYC.

Effective treatment of human breast tumors by chimeric CCL2 and CCL8 diphtheria toxin cytotoxic peptides.

<i>NSUN2</i> mediates <i>SALL2</i> m5C methylation to inhibit ferroptosis and promote breast cancer progression.

Targeting the PI3K/AKT pathway in prostate cancer: the role of PTEN deficiency and biomarker-guided therapy.

ABHD17C regulates the efficacy of lenvatinib in suppressing hepatocellular carcinoma.

Advances in SEC61G research: from ER translocon subunit to emerging pan-cancer oncogenic roles.

Efficacy and safety profiles of CDK4/6 inhibitor in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC) from the high-altitude <i>versus</i> low-altitude regions: a multi-center retrospective study.